hero image

Steven Holtzman to Retire from Biogen

November 11, 2015 Corporate

Steven Holtzman, executive vice president of Corporate Development, will retire from Biogen (NASDAQ: BIIB) effective in March of 2016. 

Mr. Holtzman has been executive vice president of Corporate Development at Biogen for five years.  Previously he served as founder and CEO of Infinity Pharmaceuticals, an early employee and Chief Business Officer of Millennium Pharmaceuticals, and founder and Executive Vice President of DNX Corp.

“In the five years Steve has been with Biogen he has played a critical role in our success.  He created and led our Program Leadership and Management Group through its successful prosecution of five new drug approvals as well as our Business Development and M&A group in numerous successful transactions,” said George A. Scangos, Ph.D., chief executive officer.  “While we will miss Steve’s guidance, we appreciate his contributions and wish him all the best.”

“It’s been my pleasure to have been a part of Biogen during such an important time in the Company’s history,” said Holtzman. “We’ve accomplished a great deal on behalf of patients and our shareholders during my five year tenure at Biogen. As I prepare to move back next year to working with younger-stage biotechnology companies, I’m certain that Biogen is well positioned for success long into the future.”

With Holtzman’s retirement, Adam Koppel has been promoted to the newly created position of EVP of Corporate Development and Strategy.  He will retain his position as head of the Corporate Strategy group that he has led for the past year, which will now be combined with the Business Development and M&A Group.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the Company, please visit www.biogen.com

 

Biogen
Media Contact:
Jason Glashow
+1 781-464-3260
public.affairs@biogen.com

or

Investor Contact:
Benjamin Strain
+1 781-464-2442
IR@biogen.com

thumb
February 6, 2023
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb.

thumb
January 29, 2023
Lecanemab Receives Priority Review Status in Japan

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for